Also found in: Dictionary, Wikipedia.
Related to Meridia: phentermine, Xenical, sibutramine


A central, appetite-suppressing agent that blocks reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine; it provides a sensation of fullness from lesser amounts of food, and increases metabolism. Sibutramine was approved for use as a dietary adjunct in the mid-1990s and was heavily marketed until 2010, when it was withdrawn from the market due to the increased risk of cardiovascular events and strokes associated with its use. Sibutramine is a Schedule-IV Controlled Substance.

Obese patients with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 in addition to other factors (e.g., hypertension, diabetes, dyslipidemia).

Adverse effects
Headache, dry mouth, anorexia, constipation.

Concurrent MAOIs, other central appetite suppressants, anorexia nervosa.


Sibutramine Obesity An anti-obesity agent used to facilitate and maintain weight loss, coupled to a low-calorie diet Contraindications Hx of stroke, CAD, CHF, uncontrolled HTN. See Obesity. Cf Xenical.
References in periodicals archive ?
Those who were able to achieve at least a five percent weight loss were included in the second 18-month phase of the study where they were randomized to receive either MERIDIA or placebo (with prescribed diet and exercise) to evaluate the effect of MERIDIA on patients' success at maintaining the original weight loss.
The primary goals of the lawsuit are: 1) to obtain a Court order forcing Defendants to cease and desist from the manufacture and sale of Meridia and issue a recall, 2) to inform the public that consumers of Meridia are at an increased risk of cardiac complications, 3) to provide compensation to all victims for death and personal injuries, 4) to provide a fund for all users of Meridia for medical monitoring and 5) to reimburse monies paid for the recalled product.
On March 8, 2002, the Italian Health Ministry suspended the sale of Meridia (a/k/a Reductil, Reduxade and Ectiva) following 50 reports of adverse events.
MERIDIA works by affecting chemicals in the brain involved in regulating appetite and helps people overcome one of the biggest barriers to losing weight, because it helps them feel full so they can eat less -- a feeling also known as satiety.
Vash confirmed that, "With MERIDIA, my patients now have a safe, effective and well tolerated option to help them gain control over their eating habits.
Mission Control(SM) MERIDIA(R) is open to those who are currently taking MERIDIA and those who are not.
After one year on the market, nearly two million prescriptions written by physicians nationwide and more than one million patient experiences, MERIDIA has reached a milestone in supporting our commitment to the emerging clinical and public health battles against the disease of obesity," said Michael Cheney, senior director of the obesity business unit at Knoll.
Mission Control (SM) MERIDIA(R) is open to those who are currently taking MERIDIA and those who are not.
In clinical trials of 6,000 individuals, including 4,000 obese patients, MERIDIA has been shown to be a safe and effective product.
18 /PRNewswire/ -- Knoll Pharmaceutical Company, makers of MERIDIA(R) (sibutramine hydrochloride monohydrate) C-IV Capsules, and a member of BASF Pharma, the global pharmaceutical business of BASF, announced that Reductil(R) (marketed in the United States under trade name of MERIDIA since February 1998) was granted marketing authorization on January 14, 1999 by the German regulatory agency.
This was attributed to a significant extent to the introduction of new pharmaceuticals, particularly the anti-obesity drug Meridia.